SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Earnings for SCYNEXIS, Inc. (SCYX)
Earnings in 2023 (TTM): $67.18 M
According to SCYNEXIS, Inc.'s latest financial reports the company's current earnings (TTM) are $67.18 M. The earnings displayed on this page is the company's Pretax Income.
Earnings history of SCYNEXIS, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $67.18 M | $67.04 M |
| 2022 | $-67,509,000 | $-62,809,000 |
| 2021 | $-35,954,000 | $-32,866,000 |
| 2020 | $-58,333,000 | $-55,185,000 |
| 2019 | $-53,710,000 | $-55,234,000 |
| 2018 | $-19,204,000 | $-12,468,000 |
| 2017 | $-25,060,000 | $-25,060,000 |
| 2016 | $-29,989,000 | $-29,989,000 |
| 2015 | $-28,338,000 | $-32,623,000 |
| 2014 | $-6,769,000 | $-4,234,000 |
| 2013 | $-30,461,000 | $-30,461,000 |
| 2012 | $-11,477,000 | $-11,477,000 |